Overview
Spastic cerebral palsy (CP) is the most common subtype of CP, characterized by increased muscle tone and stiffness, particularly affecting motor functions. This condition predominantly impacts motor development, leading to difficulties in movement, posture, and coordination. Children with spastic CP often exhibit a spectrum of impairments ranging from mild motor challenges to severe disability, depending on the severity and distribution of spasticity. The management of spastic CP involves a multidisciplinary approach, focusing on improving functional abilities, reducing spasticity, and enhancing quality of life. Evidence from various studies highlights the importance of tailored interventions, including pharmacological treatments, physical therapies, and assistive technologies, to address the diverse needs of these patients.
Clinical Presentation
Children with spastic cerebral palsy typically present with a range of motor impairments, predominantly affecting the lower limbs in diplegic forms. Studies have focused on specific age groups and severity levels to better understand clinical manifestations and treatment responses. For instance, a study involving children aged 4 to 12 years with diplegic CP receiving botulinum toxin type-A (BoNT-A) injections underscored the necessity for supplementary therapies to enhance functional outcomes [PMID:35233271]. These children often require multifaceted interventions beyond pharmacological treatments to achieve optimal motor function and daily living activities.
The functional capabilities of children with spastic CP have been further elucidated through standardized assessments. Verschuren et al. included 20 children and adolescents with spastic CP, classified as Gross Motor Function Classification System (GMFCS) levels I or II, who successfully completed both the Motor Performance Scales Test (MPST) and Wingate Anaerobic Test (WAnT) [PMID:23288003]. This suggests that even those with moderate motor impairments can participate in rigorous assessments, providing valuable insights into their anaerobic performance and motor capabilities. Such assessments are crucial for monitoring progress and tailoring interventions effectively.
Pharmacological interventions aimed at reducing spasticity and improving joint mobility have shown promising results. A study comparing eperisone and baclofen in children with spastic CP demonstrated that while both treatments reduced muscular tone, eperisone exhibited a more significant improvement in joint range of motion (-32.5% vs. -14.6% with baclofen) [PMID:19458926]. This finding highlights the potential of eperisone in managing not only spasticity but also the associated limitations in joint mobility, which are critical for functional improvement in these patients.
Diagnosis
Diagnosis of spastic cerebral palsy typically involves a comprehensive evaluation encompassing developmental history, clinical examination, and often neuroimaging studies such as MRI. Children diagnosed with diplegic CP often fall within specific GMFCS levels, reflecting the severity of their motor impairments. A notable study included participants diagnosed with diplegic CP, categorized by GMFCS levels I to III, who were already undergoing regular BoNT-A injections every 6-9 months [PMID:35233271]. This regimen serves as a benchmark for treatment adherence and severity stratification, underscoring the importance of standardized diagnostic criteria and ongoing management protocols in clinical practice.
Diagnostic criteria also consider exclusion factors that may complicate treatment outcomes or assessment accuracy. For example, severe spasticity (Modified Ashworth Scale > 3), a history of orthopedic surgeries, vasomotor instability, lower motor neuron disorders, hip-knee joint limitations, pressure ulcers, and uncontrolled epilepsy are often exclusion criteria in clinical trials [PMID:35233271]. These factors highlight the need for a thorough clinical evaluation to tailor interventions effectively and avoid potential complications.
Management
The management of spastic cerebral palsy is multifaceted, integrating pharmacological, rehabilitative, and assistive interventions to optimize functional outcomes. FES-cycling therapy has emerged as a promising adjunctive treatment, particularly for children with diplegic CP classified as GMFCS levels I to III [PMID:35233271]. This therapy has been shown to significantly enhance motor function, improve walking patterns, reduce spasticity, and boost daily living activities and aerobic capacity compared to standard treatments alone. The comprehensive benefits suggest that FES-cycling could be a valuable component of long-term management strategies, contributing to sustained improvements in quality of life and functional independence.
Exercise interventions, including both aerobic and anaerobic assessments, play a crucial role in evaluating and enhancing physical capabilities. Verschuren et al. demonstrated very strong correlations between the Motor Performance Scales Test (MPST) and Wingate Anaerobic Test (WAnT) results in children with spastic CP, indicating that MPST can effectively gauge anaerobic performance [PMID:23288003]. This correlation supports the use of MPST as a practical tool for clinicians to monitor progress in anaerobic capacity, which is essential for designing targeted exercise programs that improve overall motor function and endurance.
Pharmacological treatments continue to be pivotal in managing spasticity and improving functional outcomes. A randomized trial comparing eperisone and baclofen in children with spastic CP revealed significant improvements in lower limb functionality and reduced muscular tone with both drugs [PMID:19458926]. However, eperisone demonstrated superior benefits in upper limb function and joint range of motion, alongside a more favorable tolerability profile, with fewer adverse events reported compared to baclofen. These findings suggest that eperisone may be a preferred option in certain clinical scenarios, particularly when upper limb involvement and joint mobility are significant concerns.
Complications
Children with spastic cerebral palsy are susceptible to various complications that can significantly impact their quality of life and treatment outcomes. Severe spasticity, often measured by a Modified Ashworth Scale (MAS) score greater than 3, poses a substantial challenge and may necessitate more aggressive interventions [PMID:35233271]. Additionally, a history of orthopedic surgeries, vasomotor instability, lower motor neuron disorders, hip-knee joint limitations, pressure ulcers, and uncontrolled epilepsy are common exclusion criteria in clinical trials due to their potential to complicate treatment efficacy and patient safety [PMID:35233271]. These factors highlight the importance of comprehensive pre-treatment assessments to identify and manage these risks effectively.
Orthopedic complications, such as hip dislocation and contractures, are frequent in spastic CP and can severely limit mobility and functional independence. Pressure ulcers, often related to immobility and altered pressure distribution, are another significant concern, necessitating vigilant skin care and positioning strategies. Neurological issues, including seizures, further complicate management, requiring careful coordination between neurologists and other healthcare providers to ensure optimal control and minimize adverse effects on motor function and overall health.
Prognosis & Follow-up
The prognosis for children with spastic cerebral palsy varies widely based on the severity of motor impairments and the effectiveness of interventions. Long-term follow-up studies suggest that comprehensive management strategies, including FES-cycling therapy, can lead to sustained improvements in motor function, walking patterns, and aerobic capacity [PMID:35233271]. These enhancements not only improve physical capabilities but also contribute positively to psychosocial well-being and independence in daily activities. Regular assessments using tools like the MPST and WAnT can provide valuable insights into the progression of motor skills and anaerobic performance, guiding adjustments in therapeutic approaches as needed [PMID:23288003].
Pharmacological interventions also play a crucial role in long-term prognosis. Both eperisone and baclofen have demonstrated significant reductions in walking times and improvements in reflex functions, with eperisone showing early effects within weeks of initiation [PMID:19458926]. Early clinical follow-up assessments can help monitor these improvements and address any emerging issues promptly, ensuring that treatment plans remain effective and adaptive to the evolving needs of the patient. Regular evaluations are essential for maintaining optimal functional gains and adapting interventions to prevent secondary complications, thereby supporting a positive long-term prognosis.
Key Recommendations
References
1 Özen N, Unlu E, Karaahmet OZ, Gurcay E, Gundogdu I, Umay E. Effectiveness of Functional Electrical Stimulation - Cycling Treatment in Children with Cerebral Palsy. Malawi medical journal : the journal of Medical Association of Malawi 2021. link 2 Verschuren O, Bongers BC, Obeid J, Ruyten T, Takken T. Validity of the muscle power sprint test in ambulatory youth with cerebral palsy. Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association 2013. link 3 Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. Advances in therapy 2009. link